Brookmont Capital Management Sells 940 Shares of Gilead Sciences, Inc. $GILD

Brookmont Capital Management trimmed its stake in Gilead Sciences, Inc. (NASDAQ:GILD) by 2.4% during the 2nd quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 37,551 shares of the biopharmaceutical company’s stock after selling 940 shares during the period. Gilead Sciences comprises about 2.4% of Brookmont Capital Management’s investment portfolio, making the stock its 9th biggest position. Brookmont Capital Management’s holdings in Gilead Sciences were worth $4,163,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Other hedge funds and other institutional investors also recently bought and sold shares of the company. Smallwood Wealth Investment Management LLC acquired a new stake in Gilead Sciences in the 1st quarter worth $25,000. Activest Wealth Management grew its position in Gilead Sciences by 2,837.5% in the 1st quarter. Activest Wealth Management now owns 235 shares of the biopharmaceutical company’s stock worth $26,000 after purchasing an additional 227 shares during the last quarter. Goodman Advisory Group LLC acquired a new stake in Gilead Sciences in the 1st quarter worth $29,000. Colonial Trust Advisors grew its position in Gilead Sciences by 304.3% in the 1st quarter. Colonial Trust Advisors now owns 283 shares of the biopharmaceutical company’s stock worth $32,000 after purchasing an additional 213 shares during the last quarter. Finally, Core Alternative Capital grew its position in Gilead Sciences by 370.8% in the 1st quarter. Core Alternative Capital now owns 306 shares of the biopharmaceutical company’s stock worth $34,000 after purchasing an additional 241 shares during the last quarter. 83.67% of the stock is currently owned by institutional investors and hedge funds.

Gilead Sciences Trading Up 0.1%

Shares of GILD stock opened at $111.15 on Thursday. Gilead Sciences, Inc. has a 12-month low of $83.10 and a 12-month high of $121.83. The company has a market capitalization of $137.92 billion, a P/E ratio of 22.14, a P/E/G ratio of 0.75 and a beta of 0.34. The firm has a 50-day moving average price of $114.47 and a 200 day moving average price of $109.92. The company has a quick ratio of 1.15, a current ratio of 1.32 and a debt-to-equity ratio of 1.13.

Gilead Sciences (NASDAQ:GILD) last announced its quarterly earnings results on Thursday, August 7th. The biopharmaceutical company reported $2.01 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.96 by $0.05. Gilead Sciences had a net margin of 21.86% and a return on equity of 50.99%. The firm had revenue of $7.08 billion during the quarter, compared to the consensus estimate of $6.95 billion. During the same period last year, the firm posted $2.01 EPS. The firm’s quarterly revenue was up 1.4% on a year-over-year basis. Gilead Sciences has set its FY 2025 guidance at 7.950-8.250 EPS. Research analysts forecast that Gilead Sciences, Inc. will post 7.95 earnings per share for the current fiscal year.

Gilead Sciences Announces Dividend

The business also recently disclosed a quarterly dividend, which was paid on Monday, September 29th. Shareholders of record on Monday, September 15th were given a $0.79 dividend. This represents a $3.16 annualized dividend and a yield of 2.8%. The ex-dividend date was Monday, September 15th. Gilead Sciences’s dividend payout ratio (DPR) is presently 62.95%.

Wall Street Analysts Forecast Growth

GILD has been the topic of several research analyst reports. Royal Bank Of Canada raised their price target on shares of Gilead Sciences from $96.00 to $98.00 and gave the stock a “sector perform” rating in a research report on Friday, August 8th. Rothschild & Co Redburn raised their price objective on shares of Gilead Sciences from $136.00 to $143.00 and gave the stock a “buy” rating in a report on Friday, September 12th. Dbs Bank raised shares of Gilead Sciences to a “moderate buy” rating in a report on Friday, September 5th. Daiwa Capital Markets raised shares of Gilead Sciences from a “neutral” rating to an “outperform” rating and set a $128.00 price objective for the company in a report on Tuesday, August 19th. Finally, Truist Financial raised shares of Gilead Sciences from a “hold” rating to a “buy” rating and raised their price objective for the stock from $108.00 to $127.00 in a report on Friday, August 8th. Three investment analysts have rated the stock with a Strong Buy rating, nineteen have given a Buy rating and six have issued a Hold rating to the company. According to MarketBeat.com, Gilead Sciences presently has an average rating of “Moderate Buy” and a consensus price target of $117.17.

Insider Buying and Selling at Gilead Sciences

In other Gilead Sciences news, CEO Daniel Patrick O’day sold 10,000 shares of the firm’s stock in a transaction dated Monday, September 29th. The shares were sold at an average price of $111.66, for a total value of $1,116,600.00. Following the completion of the sale, the chief executive officer owned 591,203 shares in the company, valued at approximately $66,013,726.98. This trade represents a 1.66% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. Also, CFO Andrew D. Dickinson sold 2,500 shares of the firm’s stock in a transaction dated Monday, September 15th. The shares were sold at an average price of $113.57, for a total transaction of $283,925.00. Following the completion of the sale, the chief financial officer owned 159,555 shares of the company’s stock, valued at $18,120,661.35. The trade was a 1.54% decrease in their position. The disclosure for this sale can be found here. In the last 90 days, insiders sold 82,000 shares of company stock worth $9,402,130. 0.27% of the stock is currently owned by corporate insiders.

About Gilead Sciences

Gilead Sciences, Inc, a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis.